by Matteo Zignol, Anna S. Dean, Dennis Falzon et al.
N Engl J Med 2016; 375:1081-1089, September 15, 2016
9 pp. 629 kB
It was only in the early 1990s that drug-resistant tuberculosis began to receive global attention as a public health threat. This coincided with the detection of outbreaks of multi-drug-resistant (MDR) tuberculosis (defined as resistance to at least rifampin and isoniazid) that were associated with high mortality among patients co-infected with the human immunodeficiency virus (HIV). The urgent need for a global mechanism to monitor the emergence and spread of resistance to antituberculosis drugs became clear.